Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis

Beth L Laube, Gail Sharpless, Kathryn A Carson, Amber Kelly, Peter J Mogayzel Jr, Beth L Laube, Gail Sharpless, Kathryn A Carson, Amber Kelly, Peter J Mogayzel Jr

Abstract

Background: Little is known of how mucociliary clearance (MCC) in children with cystic fibrosis (CF) and normal pulmonary function compares with healthy adults, or how an acute inhalation of 7% hypertonic saline (HS) aerosol affects MCC in these same children.

Methods: We compared MCC in 12 children with CF and normal pulmonary function after an acute inhalation of 0.12% saline (placebo), or HS, admixed with the radioisotope 99 mtechnetium sulfur colloid in a double-blind, randomized, cross-over study. Mucociliary clearance on the placebo day in the children was also compared to MCC in 10 healthy, non-CF adults. Mucociliary clearance was quantified over a 90 min period, using gamma scintigraphy, and is reported as MCC at 60 min (MCC60) and 90 min (MCC90).

Results: Median [interquartile range] MCC60 and MCC90 in the children on the placebo visit were 15.4 [12.4-24.5]% and 19.3 [17.3-27.8%]%, respectively, which were similar to the adults with 17.8 [6.4-28.7]% and 29.6 [16.1-43.5]%, respectively. There was no significant improvement in MCC60 (2.2 [-6.2-11.8]%) or MCC90 (2.3 [-1.2-10.5]%) with HS, compared to placebo. In addition, 5/12 and 4/12 of the children showed a decrease in MCC60 and MCC90, respectively, after inhalation of HS. A post hoc subgroup analysis of the change in MCC90 after HS showed a significantly greater improvement in MCC in children with lower placebo MCC90 compared to those with higher placebo MCC90 (p = 0.045).

Conclusions: These data suggest that percent MCC varies significantly between children with CF lung disease and normal pulmonary functions, with some children demonstrating MCC values within the normal range and others showing MCC values that are below normal values. In addition, although MCC did not improve in all children after inhalation of HS, improvement did occur in children with relatively low MCC values after placebo. This finding suggests that acute inhalation of hypertonic saline may benefit a subset of children with low MCC values.

Trial registration: ClinicalTrials.gov NCT01293084.

Figures

Figure 1
Figure 1
Effect of hypertonic saline inhalation on mucociliary clearance in individual children (Red - Female patients; Blue - Male patients).
Figure 2
Figure 2
Box plots showing median and interquartile range for mucociliary clearance at 60 min on the placebo and HS visits for all children and for subgroups of children with less than or greater than the median MCC60 after placebo. The "whiskers" represent the 10th and 90th percentiles. Open circles represent data outside the 10th and 90th percentiles. The change in MCC with HS was not significantly different from placebo for all children, or for the subgroup comparison.
Figure 3
Figure 3
Box plots showing median and interquartile range for mucociliary clearance at 90 min on the placebo and HS visits for all children and for children with less than or greater than the median MCC90 after placebo. The "whiskers" represent the 10th and 90th percentiles. Open circles represent data outside the 10th and 90th percentiles. The change in MCC with HS was not significantly different from placebo for all children, but was significantly different for the comparison of the subgroups (p = 0.045).

References

    1. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Internal Med. 2007;261:5–16. doi: 10.1111/j.1365-2796.2006.01744.x.
    1. Rubin BK. Mucus, phlegm, and sputum in cystic fibrosis. Respir Care. 2009;54:726–732; discussion 732. doi: 10.4187/002013209790983269.
    1. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med. 1996;153:1503–1509.
    1. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, King M, Bye PT. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997;52:900–903. doi: 10.1136/thx.52.10.900.
    1. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241–250. doi: 10.1056/NEJMoa043891.
    1. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957–969. doi: 10.1164/rccm.200705-664OC.
    1. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–240. doi: 10.1056/NEJMoa043900.
    1. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Ped Pulmonol. 1996;21:77–83. doi: 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>;2-M.
    1. Cystic Fibrosis Foundation Patient Registr. annual data report. Bethesda, Maryland; 2008.
    1. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med. 2007;175:822–828. doi: 10.1164/rccm.200609-1354OC.
    1. Suri R, Marshall LJ, Wallis C, Metcalfe C, Shute JK, Bush A. Safety and use of sputum induction in children with cystic fibrosis. Ped Pulmonol. 2003;35:309–313. doi: 10.1002/ppul.10226.
    1. Laube BL, Norman PS, Wagner HN Jr, Adams GK III. The effect of aerosol distribution on airway responsiveness to inhaled methacholine in patients with asthma. J Allergy Clin Immunol. 1992;89:510–518. doi: 10.1016/0091-6749(92)90317-U.
    1. Cleary JC, Karmazyn YJ, Mogayzel PJ Jr, Laube BL. Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects. Pulmonary Pharmacology & Therapeutics. 2008;21:105–11. doi: 10.1016/j.pupt.2007.01.002.
    1. Mortensen J, Hansen A, Falk M, Nielsen IK, Groth S. Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest. 1993;103:805–811. doi: 10.1378/chest.103.3.805.
    1. Mortensen J, Groth S, Lange P, Hermansen F. Effect of terbutaline on mucociliary clearance in asthmatic and healthy subjects after inhalation from a pressurized inhaler and a dry powder inhaler. Thorax. 1991. pp. 817–823.
    1. McShane D, Davies JC, Wodehouse T, Bush A, Geddes D, Alton EWFW. Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect. Eur Respir J. 2004. pp. 95–100.
    1. Kellerman D, Mospan AR, Engels J, Schaberg A, Gorden J, Denufosol Smiley L. A review of studies with inhaled P2Y2 agonists that led to Phase 3. Pulmonary Pharmacol & Therapeutics. 2008;21:600–607. doi: 10.1016/j.pupt.2007.12.003.
    1. Amin R, Subbarao P, Jaber A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax. 2010;65:379–383. doi: 10.1136/thx.2009.125831.

Source: PubMed

3
Abonneren